article · Toxicology and Applied Pharmacology

Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling

202062 citationsKafr el-Sheikh University

In plain language

No abstract is available for this record, so no summary has been generated.

Research topics

Liver physiology and pathology
Drug Transport and Resistance Mechanisms
Drug-Induced Hepatotoxicity and Protection

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1016/j.taap.2020.115246

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.